177results about How to "Lower uric acid levels" patented technology

[Problems] The present invention provides pharmaceutical composition which is effective for the prophylaxis or treatment of pathology showing involvement of uric acid (hyperuricemia, gouty tophus, acute gout arthritis, chronic gout arthritis, gouty kidney, urolithiasis, renal function disorder, coronary arterial disease, ischemic heart disease and the like) and the like, and is superior in the time-course stability and dissolution property (disintegration property).[Solving Means] The pharmaceutical composition of the present invention is a pharmaceutical composition comprising a nitrogen-containing fused ring compound represented by the following formula [1] or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable additives, wherein the nitrogen-containing fused ring compound or a pharmaceutically acceptable salt thereof is not in contact with a basic additive:wherein each symbol is as described in the specification.

Disclosed is a method for lowering elevated uric acid levels in a patient having a plasma level of uric acid (pUAc) of more than about 6 mg / dL, the method consisting of administering to said patient an intravenous injections every 2 to 4 weeks of about 8 mg PEG-uricase.

Provided herein are methods and compositions and kits related to uricase compositions and / or compositions comprising synthetic nanocarriers comprising an immunosuppressant. Also provided herein are methods and compositions and kits for the treatment of subjects, including subjects with hyperuricemia, gout or a condition associated with gout, and for preventing gout flare.

A compound represented by following general formula (I):wherein, represents a single bond or a double bond; L represents —NH— or the like; X1 represents N or C, provided that in the case where X1 is N, X2 represents C—R and in the case where X1 is C, X2 represents N—R1 or the like; Y's may be either the same or different and represent CH2 or the like; A represents a non-natural sugar residue represented by following general formula:wherein, m represents 0 to 1; represents a single bond or a double bond; X represents O or the like; R3 to R8 may be either the same or different and represent hydroxy group or the like; and B represents a group represented by following general formula:wherein, n and k represent 0 to 5; represents a single bond or a double bond; Z1 to Z16 may be either the same or different and represent CH or the like; R10 and R11 may be either the same or different and represent a lower alkoxy group having 1 to 5 carbon atoms or the like; and R15 represents a hydrogen atom or the like, a pharmaceutically acceptable salt thereof, a prodrug thereof, a hydrate thereof or solvate thereof. Because of having an excellent CNT2 inhibitory activity and showing a high in vivo stability and stable physicochemical properties, the aforesaid compound is useful as a remedy for hyperuricemia.

A composition composed of a Lactobacillus bacterium, Bifidobacterium longum, and xylooligosaccharide is provided for use in reducing uric acid levels in the blood and preventing or treating hyperuricemia or gout.

The invention relates to a method for preparing bonito stick protein hydrolysate with an effect of reducing uric acid. The method comprises the following main steps of raw material heat treatment, restriction digestion, membrane separation-anion exchange chromatography-gel filtration chromatography separation, concentration and spray drying so as to obtain the bonito stick protein hydrolysate with an effect of reducing uric acid. The amino acid analysis indicates that the zymolyte peptide fragment primary amino acid sequence contains four amino acids, namely histidine, arginine, lysine and threonine, the total mass content of the four amino acids is 70 percent of the total amino acid content of zymolyte. MALDI-TOF-MS mass spectrum determines that the molecular weight of the main peptide effective ingredient is less than 700Da. In-vitro uric acid reduction experiments prove that the bonito stick protein hydrolysate has a remarkable effect of inhibiting generation of uric acid, and has an inhibition rate over 50 percent; an oteracil potassium molded hyperuricemic rat animal model indicates that the bonito stick protein hydrolysate can be used for remarkably reducing the level of serum uric acid and serum creatinine of rats, and shows a relatively good kidney protecting effect.

The subject invention provides materials and methods for modulating a variety of biological factors to treat biological conditions associated with the factors. In one embodiment of the invention, a cysteamine compound is administered to a patient to treat hypercholesterolemia and / or complications associated with hypercholesterolemia. In another embodiment, a cysteamine compound is administered to a patient to prevent the onset of diabetes in an at-risk patient and / or treat or prevent the onset of diabetes-associated complications.

The invention discloses lactobacillus rhamnosus NX-2 and an application thereof in preparation of uric acid reducing drugs, and belongs to the technical field of microorganisms. The lactobacillus rhamnosus NX-2 disclosed by the invention has a preservation number of CGMCC No.20110. Non-inactivated and inactivated fermentation supernate, bacterial suspension and cell disruption material supernate of the lactobacillus rhamnosus NX-2 have uric acid reducing effects on a zebrafish high-uric-acid model, and can inhibit the activity of xanthine oxidase in the body of a high-uric-acid zebrafish. Thelactobacillus rhamnosus NX-2 disclosed by the invention has a huge potential application prospect in the aspect of preparing medicines for treating and / or preventing hyperuricemia.

The invention discloses an L.plantarum UA149 strain and an application thereof, and belongs to the field of functional food microorganisms. The L.plantarum UA149 strain is deposited in China Typical Culture Collection Center on November 29, 2018 with the preservation number of CCTCC No: M2018842. The strain can be apply to preparing products with a uric acid reducing function or a gout resisting function. Lactic acid bacteria separated and identified from the surface of fleshy plant leaves are taken as research objects, and a new strain of lactic acid bacteria is screened through a large number of experiments. Hyperuricemia model rats are established by potassium oxazinate combined with fructose water, continuous intragastric administration of the lactobacillus plantarum UA149 strain for 14 days can significantly reduce the level of uric acid; and during gout attack, the release of inflammatory factors thromboxane and leukotriene mediated by neutrophils is reduced, the influx of neutrophils into joints is avoided, and the symptoms of redness, swelling, pain, heat and the like are reduced.

The invention relates to a pharmaceutical composition for rapidly reducing content of uric acid in individual blood, which comprises anserine in an amount larger than 50 mg to about 600 mg. the invention further relates to a package that comprises the pharmaceutical composition including anserine, and tags and / or inserts indicative of administering the composition to individual to offer anserine in an amount larger than 50 mg to about 600 mg per dosage. In addition, the invention relates to uses of anserine in the manufacturing of medicines for rapidly reducing content of uric acid in individual blood, wherein the medicine includes anserine in an amount larger than 50 mg to about 600 mg.

A method for inhibiting xanthine oxidase and for reducing uric acid levels using a composition obtained by culturing Lactobacillus rhamnosus in a medium. Also disclosed is a composition including a metabolite of Lactobacillus rhamnosus for reducing uric acid levels in a subject and a method for producing the composition.

The invention relates to the technical field of health products, especially to a composition capable of decreasing uric acid and a preparation thereof. The composition capable of decreasing uric acid comprises skipjack extract and traditional Chinese medicine extract. After combined usage of the skipjack extract and the traditional Chinese medicine extract, better uric acid decreasing effect is obtained under the condition of reduction in dosage.

The invention relates to the field of microorganisms, and discloses lactobacillus fermentum capable of reducing blood uric acid. The strain is named 2644 strain, and is preserved at the China GeneralMicrobiological Culture Collection Center on 19th, November, 2018, and a microbial preservation number is CGMCC NO.16754; and the preservation authority address is NO.3 1# Courtyard, Beichen West Road, Chaoyang District, Beijing, and the microorganism is classified and named Lactobacillus fermentum. The strain can effectively reduce the content of the blood uric acid; and not only can intake of exogenous purines be reduced, but also discharge of internal uric acid from an intestinal tract can be promoted so that the blood uric acid level of a body can be more effectively controlled.

The present invention discloses a method for the preparation of a protein peptide, peptide powder prepared thereby, and use of the peptide powder in hypouricemic food products or health care products. The peptide powder is capable of inhibiting the activity of xanthine oxidase and effectively reducing uric acid. The method in an example of the present invention comprises: mincing the tuna, heating with steam or water to obtain a pretreated tuna, enzymolysing the pretreated tuna, deactivating the enzyme, centrifuging, removing impurities to obtain a supernatant, concentrating, and drying to obtain the peptide powder of interest.

Methods and compositions for treating and / or preventing hyperuricemia or metabolic disorders associated with hyperuricemia comprising administering to a patient in need a therapeutically effective amount of diacerein, rhein, or a pharmaceutically acceptable salt, an analog, a prodrug, or an active metabolite thereof.

The invention discloses an alga ferment nutritional solid drink. The alga ferment nutritional solid drink is prepared from the following raw materials in percentage by weight: 10-15% of spirulina, 12-28% of chlorella pyrenoidosa powder, 12-28% of euglenophyta, 15% of alpha-amylase, 5% of lipase, 25% of cellulase and 5% of protease. A preparation process of the alga ferment nutritional solid drink comprises the following steps: (1) selecting and baking the materials; (2) drying; (3) crushing, purifying and sterilizing; (4) mixing; (5) carrying out incense enhancing and equalization treatment; (6) packaging. Compared with the prior art, the alga ferment nutritional solid drink has the advantages that natural raw materials serve as effective ingredients, and the intake and absorption of villi are controlled in the intestinal tract; the metabolic balance of the intestinal tract is regulated, and the value of uric acid in blood can be more effectively reduced; gout is prevented and improved, the propagation of beneficial bacteria of the intestinal tract is improved, the breeding of miscellaneous bacteria of the intestinal tract is inhibited, and the content of oxygen in the blood is increased; the immune system is regulated, and the immunity is enhanced.

The invention discloses a traditional Chinese medicine composition for treating gout. The traditional Chinese medicine composition for treating gout is prepared from the following raw materials in parts by weight: 8-12 parts of salvia miltiorrhiza, 6.75-12 parts of polygonum cuspidatum, 6.75-9 parts of radices sileris, 6.75-12 parts of gentiana macrophylla, 9-12 parts of scutellaria baicalensis, 4.5-8 parts of rhizoma corydalis, 4.5-8 parts of cassia twig and 6.75-12 parts of medlar. The traditional Chinese medicine composition for treating gout, which is provided by the invention, has remarkable anti-inflammatory and abirritation effects, is capable of remarkably lowering the content of blood uric acid, good in treatment effect on gout, short in treatment period, low in cost, and free from obvious toxic and side effects and adverse reactions, and provides a new choice for clinic.

Methods and compositions for treating and / or preventing hyperuricemia or metabolic disorders associated with hyperuricemia comprising administering to a patient in need a therapeutically effective amount of diacerein, rhein, or a pharmaceutically acceptable salt, an analog, a prodrug, or an active metabolite thereof.

The invention provides an externally applied medicine for treating gout and a preparation method thereof. The preparation method comprises the following steps: respectively soaking sunflower, buckwheat root, Philippine flemingia root, Pittosporum glabratum Lindl and Paris polyphylla in boiled rice vinegar; inoculating Acetobacter sp. GLYSM66 CCTCC NO:M2011238, and fermenting for different fermentation times; and blending the fermentation liquids to obtain the externally applied medicine for treating gout. The externally applied medicine has the functions of dredging the channels and quickly lowering the uric acid level in the blood of a patient with gout, and has the advantages of quick pain alleviating, good curative effect, low cost, no toxic or side effect and simple preparation method.

The present disclosure relates to erythroid cells that have been engineered to comprise a uricase, a uric acid transporter, or both a uricase and a uric acid transporter. The engineered erythroid cells of the present disclosure are useful in degrading uric acid inside the engineered erythroid cell. The engineered erythroid cells of the present disclosure are useful in methods of treating hyperuricemia. The engineered erythroid cells of the present disclosure are also useful in methods of treating gout, and in particular chronic refractory gout.

The invention relates to application of a phellinus igniarius aqueous extract in trioxypurine resistance. The phellinus igniarius aqueous extract mainly comprises two substances with mass-to-charge ratio of 1015.0270 and 1029.2048 daltons; the spectral strength of the two substances in mass spectrometric detection is 60% and 100%. A phellinus igniarius alcohol is prepared according to the following method: crushing phellinus igniarius growing in Changbai Mountain region into powder; adding water to the phellinus igniarius powder, and uniformly stirring; boiling for 2h in a boiling water bath to obtain a mixed solution; cooling the mixed solution; centrifuging at superspeed; collecting supernate; filtering the supernate to obtain the phellinus igniarius aqueous extract; sterilizing under the temperature of 121 DEG C and high pressure to obtain the phellinus igniarius aqueous extract. Compared with colchicine, the phellinus igniarius aqueous extract has the effect of reducing depositingtrioxypurine in articular cavity, so that the trioxypurine content in a human body can be reduced through the phellinus igniarius aqueous extract, to treat gout.

The invention discloses a plant composition for treating hyperuricemia and gout and plant composition solid granules. The plant composition is prepared from celery seed extract, corn silk powder, pumpkin powder, lotus leaf powder, mulberry powder, ginseng powder grape powder by mixing. The plant composition solid granules are mainly prepared from the plant composition. According to the plant composition for treating the hyperuricemia and the gout and the plant composition solid granules, the celery seed extract, the corn silk powder, the pumpkin powder, the lotus leaf powder, the mulberry powder, the ginseng powder and the grape powder are compounded for use to improve the nutritional compositions, and the celery seed extract can significantly reduce the serum uric acid level and the urineuric acid level of the hyperuricemia; the corn silk powder and the lotus leaf powder can accelerate urinary excretion and help uric acid excretion; and the pumpkin powder, the mulberry powder, the ginseng powder and the grape powder have the functions of nourishing the liver and kidney, enhancing immunity and protecting the liver and kidney. The action mechanism of each component is different, multi-component mixing effectively exerts the synergistic effect between the components, the action time is prolonged, the curative effect is enhanced, and the components are homologous to medicine andfood, are safe and have no side effects.

The invention discloses applications of cannabidiol in preparing medicines for treating gouty arthritis. For the first time, the inventor finds that cannabidiol has the effect of obviously reducing creatinine and uric acid in serum of mice suffering from hyperuricemia, so that the hyperuricemia can be prevented and treated; meanwhile, cannabidiol can regulate the cell factors of the body, effectively resist inflammation, and alleviate gouty arthritis symptoms, and has treatment and prevention effects for the gouty arthritis. The invention further provides medicinal preparations of cannabidiol for treating gouty arthritis and corresponding medicinal dosage forms of the medicinal preparations, the medicines with different dosage forms used clinically can be prepared with a conventional preparation method, and the use is convenient.

The invention relates to a galloyl-glucoside derivative, application of a pharmaceutically acceptable salt of the galloyl-glucoside derivative to preparation of a medicine for treating hyperuricemia or gout, and a pharmaceutical composition for treating hyperuricemia or gout. The structural general formula of the galloyl-glucoside derivative is as shown in the description, wherein R1-R5 are independently selected from H or galloyl. The galloyl-glucoside derivative and the pharmaceutically acceptable salt of the galloyl-glucoside derivative have a remarkable inhibiting effect on xanthine oxidase and can remarkably reduce the uric acid level in blood serum.

Sodium 2-(5-bromo-4-(4-cyclopropyl-naphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetate is described. In addition, pharmaceutical compositions and uses such compositions for the treatment of a variety of diseases and conditions.

Sodium 2-(5-bromo-4-(4-cyclopropyl-naphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetate is described. In addition, pharmaceutical compositions and uses such compositions for the treatment of a variety of diseases and conditions.

The present invention relates to a composition for tissue preservation, and more particularly to a placenta preservation solution and a preparation method thereof. The placenta preservation solution comprises, in 1000 ml of an aqueous solution, 204 mg to 340 mg of potassium dihydrogen phosphate, 1.40 g to 1.50 g of disodium hydrogen phosphate, 7.6 g to 8.2 g of sodium chloride, 149 mg to 261 mg ofpotassium chloride, 100000U-1000000U of penicillin, 60mg-100mg of streptomycin, 12.5g of glucose, 5g of dextran-40, 7.35g of trisodium citrate and 352mg-528mg of vitamin C, and solution pH is 7.33-7.83. The placenta preservation solution is simple in components, stable and safe, has no toxic side effects, and has low cost. The placenta preservation solution is simple in preparation process and can be prepared in a large amount in a short time.

The invention discloses an oral thick paste preventing gout. The oral thick paste is prepared from 1-10 parts by weight of euglena, 1-15 parts by weight of herba lophatheri, 1-20 parts by weight of poria cocos, 1-20 parts by weight of radix puerariae, 1-20 parts by weight of bean of white hyacinth dolichos, 1-20 parts by weight of herba taraxaci, 1-15 parts by weight of curcuma longa, 1-10 parts by weight of ocean fish oligopeptide, and 30-80 parts by weight of honey. The oral thick paste has the advantages of diminishing inflammation and relieving pain, removing urate, lowering uric acid, andpreventing gout. The invention further discloses a method of preparing the oral thick paste preventing gout.

The purpose of the present invention is to provide a novel therapeutic or prophylactic agent for tumor lysis syndrome. The present invention is a therapeutic or prophylactic agent for tumor lysis syndrome, which comprises a 2-phenylthiazole compound represented by formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.

The invention provides an application of aspergillus terreus secondary metabolite-butyrolactone in preparation of a medicament for treating diabetes, and belongs to the technical field of microbial medicaments. The aspergillus terreus secondary metabolite-butyrolactone comprises butyrolactone I, wherein the butyrolactone I is extracted according to the following method: fermenting aspergillus terreus OUCMDZ-2739 inoculated in fermentation broth for 25-35 days at 20-30 DEG C; filtering the fermentation broth after fermentation with denim to separate filtrate and mycelium, respectively extracting with ethyl acetate, mixing the obtained ethyl acetate extracts, and concentrating to obtain ethyl acetate solution extract; and further purifying the ethyl acetate solution extract to obtain the butyrolactone I. By the adoption of the application of the aspergillus terreus secondary metabolite-butyrolactone in the preparation of the medicament for treating diabetes, the medicament can inhibit activity of alpha-glucosidase, regulate a composition of intestinal flora, metabolize more short-chain fatty acids, reduce a uric acid level, maintain synthesis of insulin, avoid rising of a blood sugarlevel, and achieve the purpose of relieving type 2 diabetes.